Why Is Portage Biotech Stock Skyrocketing Friday?
Portage Biotech unveils new preclinical data on PORT-7, showing strong antitumor effects in mesothelioma and advancing plans for clinical trials.
CURE6d
Favorable Initial Results in Phase 1 Trial for PD-L1 Resistant Tumors
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...
Sensei Rockets on FY ’24 Results
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) shares started out sharply higher Friday. The Boston-based clinical stage biotechnology company focused on the discovery and development of next-generation ...
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors
Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study.
Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer
Oppenheimer raised the firm’s price target on Sensei Biotherapeutics (SNSE) to $4 from $3.50 and keeps an Outperform rating on the shares. The ...
Sensei Biotherapeutics reports FY24 EPS ($1.20) vs ($1.22) last year
Sensei, as we advanced solnerstotug through dose expansion and began to demonstrate its clinical potential in patients who have progressed on and are resistant to PD-(L)1 therapy” said John Celebi, ...
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 ...